Some patients who cannot tolerate the maintenance dose of 2.4 mg find that temporarily reducing to 1.7 mg for up to four weeks helps
10 , e8689 (2018)
GLP-1 gastrointestinal paralysis symptoms may include ongoing nausea, repeated vomiting, early fullness, prolonged fullness, severe bloating, upper abdominal pain, constipation, and trouble keeping food or fluids down
For women make sure it's not cycle-related hunger in the luteal phase
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
In the EU and UK, sermorelin-based research has seen increased activity, particularly in longevity medicine institutes and sports science departments